News
Proton radiotherapy in patients with nasopharyngeal carcinoma increases chances of successful treatment
Nasopharyngeal carcinoma mainly affects younger people. It tends to be aggressive but responds very well to treatment – up to 85% of patients with this diagnosis can achieve long-term tumor disappearance with proton radiotherapy, and a significant portion of patients even completely recover. The two-year treatment results for patients with very advanced nasopharyngeal tumors, which confirmed these conclusions, were published 2 years ago by a team from Prague's Proton Therapy Center (PTC).
Early Implementation of Highly Effective Therapy for Multiple Sclerosis
The ongoing debate about changing the approach to treating relapsing-remitting multiple sclerosis (RRMS) from an escalation strategy to the early implementation of highly effective therapy (HET) is…
Sequential Treatment of Schizophrenia – Interactive Case Study
Sequential treatment of schizophrenia helps psychiatrists clarify the stage of the patient's treatment and how to further guide pharmacotherapy. The following case study illustrates the possibilities...
Treatment Options for Advanced Parkinson's Disease Using Medical Devices (DAT)
A new treatment option for advanced Parkinson's disease (PD) using medical devices (DAT − device-aided therapy) is the intestinal infusion gel containing levodopa, entacapone, and carbidopa (LECIG).…
Identification of patients with advanced Parkinson's disease suitable for device-aided therapy (DAT)
To properly implement device-aided therapy in Parkinson's disease (PD) management, it is essential to timely identify patients in advanced stages of the disease who might benefit from this…
Do real-world clinical practice data confirm the results of cenobamate treatment in the clinical program?
A recent study by Spanish authors presents the largest dataset of patients with published cenobamate treatment results under prolonged observation in real-world clinical practice at the time of…
Cenobamate in the Therapy of Pharmacoresistant Epilepsy in a Warfarinized Patient – A Case Study
A case study from Czech practice presents a patient with pharmacoresistant epilepsy and concurrent warfarin medication for heart valve replacement, where the INR value remained within the…
Meta-analysis of Efficacy and Safety of Antidiabetics in Treating Gestational DM
What efficacy and safety do insulin, metformin, or the sulfonylurea derivative glibenclamide (glyburide) offer in lowering glucose levels in women with gestational diabetes? The authors of a…
Revolutionary Change in the Paradigm of Multiple Sclerosis (MS) Treatment in the Czech Republic
At the beginning of last year, there was a revolutionary change in the paradigm of multiple sclerosis (MS) treatment in the Czech Republic. Patients with MS and an unfavorable prognosis no longer have...
How to Determine the Optimal Target Value of Intraocular Pressure in Glaucoma Treatment?
Glaucoma remains the second most common cause of blindness in Europe. Therapy needs to be individualized with regard to the severity of the condition, expected lifespan, and the rate of disease…
Hypertrophic Cardiomyopathy: When Bigger Does Not Mean Better
Hypertrophic cardiomyopathy (HCM) is a hereditary disease that, in some patients, proceeds asymptomatically, while others struggle with arrhythmias or heart failure, and in some individuals, the…
Why does the heart enlarge? Myosin mutation and hypertrophic cardiomyopathy may be the culprits
The genetic basis of hypertrophic cardiomyopathy was discovered only about a quarter-century ago. Since then, researchers have gathered a wealth of knowledge about the effects of causal mutations.…
Current View on Gestational Diabetes Mellitus in Theory and Practice
We dedicated one of the episodes of our podcast meditalks+ to the issue of gestational diabetes mellitus (GDM), focusing on aspects of care related to general practitioners. In a conversation with …
ESMO Recommendations for the Treatment of Low-Risk Myelodysplastic Syndrome
The priority in the treatment of low-risk myelodysplastic syndrome (MDS) is managing cytopenia, primarily anemia, as well as neutropenia and thrombocytopenia. The following summary of recommendations…
Effect of Luspatercept Treatment in Patients with MDS/MPN-RS-T
The presented post hoc analysis of the MEDALIST study demonstrates the effect and good tolerance of luspatercept in the rare disease from the myelodysplasia group − MDS/MPN-RS-T.